BIONOMICS LIMITED (ASX:BNO)
Industry: Pharmaceuticals, Biotechnology and Life Sciences
Activity: Developer of innovative treatments for cancer, mutiple sclerosis, anxiety and epilepsy.
31 Dalgleish Street THEBARTON SA 5031
Ph: 08 8354 6100    Fax: 08 8354 6199
Dr Deborah Rathjen
Fri, 11 Nov 2011 9:45am
Dr Deborah Rathjen, Managing Director, CEO
Dr Deborah Rathjen
Fri, 4 Nov 2011 11:25am
Deborah Rathjen, Managing Director & CEO
Dr Deborah Rathjen
Fri, 12 Aug 2011 11:30am
Dr Deborah Rathjen, Managing Director
Dr Deborah Rathjen
Thu, 13 May 2010 10:30am
BNC210 is being developed for the treatment of anxiety and depression
Icon_lastIcon_nextIcon_previousIcon_first

Executives & Directors

Managing Director, CEO
Non Exec. Director
Non Exec. Director
Secretary
Please contact the ASX to change these details

Company Podcasts

Annual General Meeting
Wed, 9 Nov 2011
Interim Results
Fri, 11 Feb 2011
Annual General Meeting
Wed, 13 Oct 2010
Annual General Meeting
Wed, 4 Nov 2009 3:00pm
EGM
Fri, 9 Oct 2009 11:00am
Full Year Results
Fri, 28 Aug 2009
Interim Results
Wed, 25 Feb 2009
Annual General Meeting
Wed, 5 Nov 2008 11:00am
Annual General Meeting
Wed, 7 Nov 2007 10:30am
Full Year Results
Tue, 21 Aug 2007
BNC105 Renal Cancer Trial Data Presented at ASCO-GU Fri, 3 Feb 2012
Appendix 4C - quarterly Tue, 31 Jan 2012
Appendix 3B Tue, 31 Jan 2012
Appendix 3B Mon, 23 Jan 2012
Appendix 3B Mon, 16 Jan 2012
CEO Update and US Investor Presentation Mon, 9 Jan 2012
CEO Biotech Showcase Presentation 2012 Mon, 9 Jan 2012
Ironwood and Bionomics Announce Agreement Thu, 5 Jan 2012
Audio Broadcast - CEO Discusses Ironwood Agreement Thu, 5 Jan 2012
Trading Halt Wed, 4 Jan 2012

Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. Boardroom Radio does not claim any association with any company listed on this site.